StockNews.AISignal intelligence
Inspire Medical Systems, Inc. · NYSE · Healthcare
Browse public INSP signals with their source context and measured market impact. Open any signal for its permanent analysis page.
INSP delivered a solid Q2 beat with EPS and revenue above expectations and raised FY2026 guidance. The updates imply stronger demand and improving profitability as reimbursement dynamics evolve. Analysts lifted targets on INSP, supporting a cautiously bullish setup into the next several quarters.
View signal analysisINSP stock surged due to a Medicare reimbursement increase announcement. Analyst upgrade from 'Hold' to 'Buy' with a $110 target price. Stock is down 38% YTD, presenting volatility concerns. High valuation ratios indicate premium pricing for growth. Financially strong but uncertain profitability amidst substantial growth investment.
View signal analysisStifel upgrades INSP to Buy, raising price target to $110. Inspire Medical sees a 50% reimbursement increase for its Inspire V implant. Advertising spending rose 56% in Q3, boosting procedure awareness. Despite a 41% drop in 2025, 10 out of 18 analysts recommend Buy. Weight-loss drugs pose risks but current valuation reflects concerns.
View signal analysisINSP reported Q3 EPS of 38 cents, exceeding expectations. Sales of $224.501M surpassed analyst projections of $220.467M. FY2025 EPS guidance raised significantly to $0.90-$1.00. Stock price jumped 17% to $86.46 post-announcement. Analysts updated price targets following earnings results.
View signal analysisINSP broke below the Cakra, indicating potential long-term bearishness. The stock has declined around 50% since its breakdown. Recovery is unlikely until the Guna Triads form around May 2028. Allegations of securities law violations add further risk to INSP. Investors are advised to avoid INSP until a constructive setup emerges.
View signal analysisINSP reported Q2 earnings of $0.45, surpassing estimates of $0.21. Company lowered FY2025 EPS guidance significantly to $0.40-$0.50. Sales guidance for FY2025 reduced to $900 million-$910 million. Analysts have downgraded price targets for INSP following disappointing guidance. Shares fell 40.6% to $77.14 after the announcement.
View signal analysis